trending Market Intelligence /marketintelligence/en/news-insights/trending/PkprghKuu6cMLSErXFEy2g2 content esgSubNav
In This List

Aclaris drug candidate clears warts in second late-stage study

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Aclaris drug candidate clears warts in second late-stage study

Aclaris Therapeutics Inc. said its common warts' treatment, A-101 45% topical solution, was more effective than placebo in a second late-stage trial.

The Wayne, Pa.-based biopharmaceutical company's drug candidate was evaluated in a phase 3 trial, called THWART-1 and WART-301, against placebo, and achieved clinical and statistical significance in removing common warts.

A-101 45% topical solution, a high concentration hydrogen peroxide solution, met the main goal as well as all secondary efficacy goals of the study, the company said.

THWART-1 was the second late-stage study which evaluated A-101 45% topical solution to treat common warts. The previous phase 3 study, dubbed THWART-2, also achieved clinical and statistical significance in clearing common warts.

THWART-1 enrolled 503 patients with up to six warts at the start of the trial who self-administered the medicine or placebo twice a week for over a period of eight weeks. A higher proportion of patients who were treated with the medicine reported their warts had cleared by day 60.

No serious side-effects related to the treatment were reported.

Aclaris said the results from the studies will serve as a basis for a New Drug Application filing and will interest partners in seeking to commercialize the drug.

There are no FDA approved prescription treatments for common warts.